AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04623346 — intervention group
Intervention type: PROCEDURE
Intervention: Observation for study group
Description: Patients with Weber B-type Ankle fractures, extraarticular wrist fractures and proximal humerus fractures were followed with conservative manner( cast or sling)
Study NCT01893996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Patients will be randomized 1:1 to receive either adalimumab or placebo for the first 26 weeks of the trial, and then after a 26 week washout period, will be crossed over into the other arm (either placebo or adalimumab) for weeks 52-78.
Study NCT01893996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03866122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NTM Monitoring
Description: NTM and a patient monitor will continuously collect temperature for up to 72 hours. Additionally, Bempu and Thermospot may monitor temperature for up to 72 hours.
Study NCT03796273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Undergo standard surgery
Study NCT03796273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo standard surgery
Study NCT03796273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Given PO
Study NCT04418791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Intermittent Fasting followed by Regular Diet
Description: Modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours). After 12 weeks of fasting, a period of 12 weeks with a regular diet follows.
Study NCT04418791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Diet followed by Modified Intermittent Fasting
Description: Regular diet means subject can eat as usual for 12 weeks. Next, a period of 12 weeks fasting follows: modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours).
Study NCT04423718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)
Description: Solution in Vial, intravitreal (IVT) injection
Study NCT04423718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)
Description: Solution in Vial, intravitreal (IVT) injection
Study NCT04423718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Description: Solution in Vial, 2 mg, intravitreal (IVT) injection
Study NCT03942289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The role of the noradrenergic system across the life span (Healthy Subjects)
Description: A sample (n=90) of balanced distribution of healthy males and females within a continuous segment of the adult life span from 20 to 80 years old will be recruited, with approximately 7 males and 7 females subjects for each decade of age. Each participant will undergo 1) a neuropsychological examination, 2) an olfactory screening and 3) a 90 min 11C-Yohimbine positron emission tomography (PET)/magnetic resonance imaging (MRI) scan in a resting state.
Study NCT03942289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The role of the noradrenergic system across the life span (Parkinson's Disease Subjects)
Description: Three groups of Parkinson Disease (PD) patients (each of them n=15) will be studied according to the duration and stage of the disease: early stage (the same group in Task 2); mid stage (5-7 years of disease duration; Hoehn and Yahr in Off 2-3); late stage (7-10 years of disease duration; Hoehn and Yahr in Off 3-4).
Study NCT02149381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBASP
Description: Cognitive behavioral group intervention for individuals suffering from chronic depression
Study NCT02149381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBASP
Description: Cognitive behavioral group intervention for individuals suffering from chronic depression
Study NCT02149381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Befriending
Description: Social support intervention, sessions once per week
Study NCT02149381 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Conventional psychiatric outpatient treatment (individual counseling)
Study NCT02149381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Conventional psychiatric outpatient treatment (individual counseling)
Study NCT03272750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bioscalin® new formulation with Galeopsis Segetum
Description: Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of study product at lunch for the first 3 months of the trial.
Study NCT03272750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference product
Description: Total duration of the study was 4 months; each subject, took by mouth two capsules/die of reference product at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
Study NCT03272750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
Study NCT04239898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red cabbage microgreens
Description: 2 cups per day
Study NCT04239898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red beet microgreens
Description: 2 cups per day
Study NCT04472052 — intervention group
Intervention type: OTHER
Intervention: appendectomy
Description: Surgical standard treatment for acute appendicitis All patients receive preoperative single-shot antibiosis, usually 2000 mg cefotaxime combined 500 mg metronidazole. Appendectomy is performed usually within 24 h of admission in patients with acute appendicitis. The laparoscopic appendectomy using the 3-trocar technique represents the surgical standard. In uncomplicated or non-perforated appendicitis, drainage is generally not required. Wounds are closed intra-cutaneous with absorbable sutures. Patients without postoperative complications are discharged home two days after surgery.
Study NCT06119126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDF1
Description: Topical SDF application
Study NCT06119126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Description: Irradiating Enamel by Diode laser
Study NCT06119126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pit Fissure Sealant
Description: Sealing occlusal pits and fissures
Study NCT02552966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UESAD
Description: Device designed to provide modest cricoid pressure to reduce reflux
Study NCT04320004 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Subject receives education
Study NCT04320004 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education with Reminder
Description: Subject receives education with reminder
Study NCT04320004 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education + Disposal Bag
Description: Subject receives education and disposal bag
Study NCT04320004 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education + Disposal Bag with Reminder
Description: Subject receives education + disposal bag with reminder
Study NCT00056095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Study NCT00056095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00056095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00056095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00056095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Study NCT00056095 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: allogeneic bone marrow transplantation
Study NCT00056095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00056095 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: peripheral blood stem cell transplantation
Study NCT01643668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
Study NCT01643668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
Study NCT01643668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Infusion
Description: Allogeneic stem cell transplantation after reduced intensity conditioning with busulfan / clofarabine chemotherapy
Study NCT02578407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: accommodative/vergence therapy
Description: 12 weekly accommodative/vergence therapies
Study NCT02719808 — intervention group
Intervention type: DRUG
Intervention: Tenofovir1
Description: receive tenofovir （300mg/d）from （28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
Study NCT02719808 — intervention group
Intervention type: DRUG
Intervention: Tenofovir2
Description: receive tenofovir （300mg/d）from（28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
Study NCT02719808 — intervention group
Intervention type: DRUG
Intervention: Tenofovir3
Description: receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
Study NCT02719808 — intervention group
Intervention type: DRUG
Intervention: Tenofovir4
Description: receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one week after delivery, it is the observational exposure.
Study NCT01985295 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pazopanib
Description: A dose escalation trial of Pazopanib, starting at 400mg daily, orally in combination with the standard 25 x 2Gy preoperative radiotherapy in newly diagnosed extremity sarcoma patients. Dose of pazopanib will be escalated via 600mg to maximally 800mg. Overall treatment time of pazopanib is 40 days.
Study NCT04471077 — intervention group
Intervention type: PROCEDURE
Intervention: bariatric surgery
Description: (Laparoscopic Sleeve Gastrectomy, laparoscopic Roux-en-Y gastric bypass)
Study NCT01893541 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ENDOSCOPIC BAND LIGATION
Description: The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
Study NCT01893541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROPRANOLOL
Description: The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
Study NCT01893541 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a multiband ligation device
Study NCT04079439 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity with tailored e-health support
Description: The planned e-health intervention will contain several elements: A motivating smartphone app registers indoor- and outdoor activity as well as activity from the use of an ergometer-bike. For recording of outdoor activity commercial wrist-born accelerometers will be used. The app-solution will be motivating and result in a reward after a predefined level of activity.
Study NCT01228279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIANEAL
Description: Weeks 1 to 6 (6 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 4-6 hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~\*same regimen as weeks 1 to 6, for both CAPD and CCPD patients
Study NCT01228279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EXTRANEAL
Description: Weeks 1 to 6 (6 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of EXTRANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and one 8-12-hour dwell of EXTRANEAL during the night
Study NCT00625131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Delivered through transdermal nicotine patch
Study NCT00625131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Smoking Cessation
Description: Manualized protocol for CBT in smoking cessation
Study NCT00625131 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Smoking Cessation
Description: Manualized protocol for CBT in smoking cessation
Study NCT00625131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion Sustained Release (SR)
Description: Antidepressant
Study NCT00625131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion Sustained Release (SR)
Description: Antidepressant
Study NCT00625131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Pre-treatment placebo transdermal patch
Study NCT02259647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg twice daily + intravenous infusion ofVit K1
Description: Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
Study NCT02259647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib 400 mg twice daily + Intravenousinfusion of placebo
Description: Sorafenib 400 mg twice daily + Intravenousinfusion ofplacebo daily for 6 days, followed by oral placebo twice daily x 3month
Study NCT01124110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics Web-Based Intervention
Description: The Tobacco Tactics Web-Based Intervention contains website, medications, and nurse counseling.
Study NCT01124110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1-800-QUIT-NOW Telephone Hotline
Description: The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
Study NCT00918281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclatide Injection
Description: Fluciclatide Injection (AH111585 (18F) Injection)
Study NCT02654782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's
Description: Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.
Study NCT02654782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Human Albumin
Description: Colloid given for hemodynamic resuscitation based off of individual patient needs.
Study NCT04321018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed meal with medium chain triglycerides
Description: Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) with medium chain triglycerides (3g/100 kcal). An amount with energy supply equivalent to their 50% basal metabolic rate.
Study NCT04321018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixed meal with medium chain triglycerides
Description: Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) with medium chain triglycerides (3g/100 kcal). An amount with energy supply equivalent to their 50% basal metabolic rate.
Study NCT04321018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed meal with the replacement of medium chain triglycerides with unsaturated tryglicerides
Description: Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) without medium chain triglycerides (replaced it with long chain triglycerides). An amount with energy supply equivalent to their 50% basal metabolic rate.
Study NCT04321018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixed meal with the replacement of medium chain triglycerides with unsaturated tryglicerides
Description: Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) without medium chain triglycerides (replaced it with long chain triglycerides). An amount with energy supply equivalent to their 50% basal metabolic rate.
Study NCT00801736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Paclitaxel
Description: * Cisplatin 75mg/m2, Day 1~* Paclitaxel 175mg/m2, Day 1
Study NCT01743469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: 1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
Study NCT02782676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Healon5 OVD
Description: ophthalmic viscosurgical device
Study NCT02782676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Healon5 OVD
Description: ophthalmic viscosurgical device
Study NCT02787564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The intervention consists of providing free fruits and vegetables of the participants' liking for a period of 4 weeks. Each week, a total of 2 portions of either fruits and/or vegetables per day will be provided.
Study NCT02285855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin treatment given at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week.
Study NCT02285855 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment given 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day.
Study NCT02285855 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Stereotactic body Radiotherapy (SBRT)
Description: SBRT delivered per standard of care practice as determined by participant's physician.
Study NCT02285855 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body Radiotherapy (SBRT)
Description: SBRT delivered per standard of care practice as determined by participant's physician.
Study NCT04662385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aloe vera toothpaste
Description: aloe vera toothpaste have antimicrobial and other multipotential effects.
Study NCT04662385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aloe vera toothpaste
Description: aloe vera toothpaste have antimicrobial and other multipotential effects.
Study NCT04662385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Total
Description: Whitening toothpaste that removes and prevents new stains Fights bacteria on teeth, tongue, cheeks and gums for whole mouth healthy Mint toothpaste for long lasting fresh breath Helps prevent plaque, tartar, cavities \& gingivitis
Study NCT04662385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Total
Description: Whitening toothpaste that removes and prevents new stains Fights bacteria on teeth, tongue, cheeks and gums for whole mouth healthy Mint toothpaste for long lasting fresh breath Helps prevent plaque, tartar, cavities \& gingivitis
Study NCT00556569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHAM JAM
Description: CHAM JAM (previously known as Moving Smart (MS) program) is a daily, 10-minute classroom-based physical activity program led by teachers that integrates academic objectives with physical activity